It has been shown that condensed triazepines exhibit important pharmacological activities [1][2][3][4]. Most of the reported condensed triazepines are from the types [1,2,5]-, [1,3,5]-, and [1,3,4]triazepines such as benzo[1,2,5]triazepines [5, 6], triazolo[1,2,5]triazepines [7], benzo[1,3,5]triazepines [8], and benzo-[1,3,4]triazepines [9]. In contrast, the biheterocyclic 1,2,4-triazepines are relativity rare. A few examples were seen in the literature such as thiazolo[1,2,4]triazepines [10, 11], oxadiazolo-and isoxazolo[1,2,4]triazepines [12], and pyrazolopyrimido[1,2,4]triazepines [13]. As a part of our program directed to the synthesis of new polynuclear bioactive heterocyclic systems [14][15][16][17], the present synthetic strategy is designed to utilize 1,6-diamino-4-(4-chlorophenyl)-2-oxopyridine-3,5-dicarbonitrile (1) as a suitable starting material for the synthesis of nitrogen bridge-head pyrido[1,2,4]triazepines of expected biological activity.It is well known that compounds having vicinal amino groups are good precursors for building many condensed heterocycles [18,19]. Compound 1 as an example of such compounds was used in the synthesis of triazolopyridines [20][21][22] and pyridotriazines [22,23], but until now only a few examples of pyrido[1,2-b]-[1,2,4]triazepines are known [22,24]. Therefore, we used compound 1 to synthesize some novel pyrido-[1,2-b][1,2,4]triazepines via ring closure reactions with some interesting 1,3-dielectrophiles. Thus, when 1,6-diamino pyridine derivative 1 was allowed to react with diethyl malonate in boiling DMF,4,3,[1,2,4]triazepine-8,10-dicarbonitrile (2) was obtained. The 1 H NMR spectrum of compound 2 showed a singlet signal at δ 3.35 ppm due to the CH 2 protons in addition to two exchangeable singlets at δ 5.67 and 8.52 ppm assigned to N−NH and C−NH protons, respectively. The treatment of compound 1 with ethyl ethoxymethylenecyanoacetate may afford two possible pyridotriazepine